NexGel

NXGL

Market cap $6.77M

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio

Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing

The transaction represents the most significant milestone in the company's history.

NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off

NEXGEL, Inc. ( NXGL ) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants Adam Levy - CEO, President & Director Joseph McGuire - Chief Financial Officer Conference Call Participants Valter Pinto - Kanan, Corbin, Schupak & Aronow, Inc. Nazibur Rahman - Maxim Group LLC, Research Division Presentation Operator Good afternoon, everyone. My name is Bo, and I will be your conference operator today.

LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its third quarter 2025 financial results for the period ending September 30, 2025.

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

NEXGEL, Inc. (NASDAQ:NXGL ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam R. Levy - CEO, President & Director Joseph F.

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.

LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 413,044 shares of its common stock (the “Shares”) at $2.30 a share. In a concurrent private placement, NEXGEL also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 206,522 shares of common stock (the “Unregistered Warrants”). The Unregistered Warrants will have an exercise price of $4.25 per share and are exercisable immediately upon issuance with a term of five years from the date of issuance.